Clozapine carries risks that no other antipsychotic does, including a potentially fatal drop in white blood cells, heart inflammation, seizures, and severe bowel complications. It is the only psychiatric medication in the United States that requires mandatory blood monitoring just to continue filling a prescription. Yet for people with treatment-resistant schizophrenia, it remains the single most effective option available, and stopping it can be more dangerous than staying on it.
The Blood Cell Risk That Changed Prescribing
The danger clozapine is most famous for is agranulocytosis, a condition where the bone marrow stops producing enough of the white blood cells that fight infection. Without those cells, even a minor bacterial infection can become life-threatening. The cumulative incidence is about 1.37% for people taking clozapine, roughly ten times higher than with other antipsychotics.
Because of this risk, anyone taking clozapine in the U.S. must be enrolled in a federal monitoring program. Blood draws are required weekly for the first six months, every two weeks from six to twelve months, and monthly after that. Prescribers check the absolute neutrophil count (a specific measure of infection-fighting cells) each time. If the count drops below a threshold of 1,500 cells per microliter for most patients, treatment is interrupted or stopped entirely. This monitoring system has made fatal agranulocytosis rare, but it also makes clozapine one of the most burdensome medications a person can take.
Heart Inflammation in the First Month
Clozapine can cause myocarditis, an inflammation of the heart muscle. Most cases develop within the first month of treatment, though the risk window extends through the first two months. Symptoms often look nothing like a “heart problem” to the person experiencing them: unexplained fatigue, shortness of breath, a racing heartbeat, low-grade fever, or chest pain. These can easily be mistaken for the flu or general medication side effects, which is part of what makes myocarditis so dangerous.
Monitoring guidelines recommend a baseline heart tracing (ECG) and blood markers for heart damage before starting clozapine, then repeating those tests at 7 and 14 days. If myocarditis is suspected, the medication is stopped immediately and the patient is referred urgently to a cardiologist. Caught early, most people recover. Missed, it can lead to lasting heart damage or death.
Seizures That Scale With Dose
Clozapine lowers the seizure threshold more than any other antipsychotic. Overall, 4% to 6% of people taking it will experience a seizure, but the risk depends heavily on dose. At doses under 300 mg per day, the seizure rate is roughly 3%. Between 325 and 500 mg per day, it climbs to about 8%. Above 500 mg per day, it jumps to as high as 38%. Blood levels of the drug matter too: seizure risk rises significantly once levels exceed roughly twice the upper therapeutic range.
This dose-dependent pattern is one reason clozapine is started at an unusually low dose, typically just 12.5 mg at bedtime, and increased by small increments every two to three days. That slow ramp-up also helps prevent dangerous drops in blood pressure, fainting, and a slowed heart rate, all of which are most common during the early titration phase. If a person misses even a few days of clozapine and needs to restart, the slow titration has to begin again from the beginning to avoid those risks.
A Gut Risk More Deadly Than Agranulocytosis
One of clozapine’s less well-known dangers is what it does to the digestive system. Clozapine slows the muscles of the gastrointestinal tract, sometimes profoundly. This can progress from constipation to a paralyzed bowel, bowel obstruction, or perforation. The mortality rate from these gut complications is estimated at ten times higher than the mortality rate from agranulocytosis.
The reason this risk flies under the radar is partly because constipation sounds minor. Many patients don’t report it, and many clinicians don’t ask about it with the same urgency they bring to blood monitoring. But severe gastrointestinal slowing can develop gradually over months or years, and by the time a bowel obstruction occurs, the situation can become surgical and life-threatening very quickly. Regular monitoring of bowel habits is critical for anyone on clozapine, even though no formal federal program requires it.
Metabolic Effects Over Time
Clozapine causes more weight gain and metabolic disruption than virtually any other psychiatric medication. In a ten-year follow-up of people started on clozapine in the U.S., the average weight gain exceeded 13.5 kilograms (about 30 pounds), and 43% developed diabetes. These are not rare side effects. They are the expected trajectory for a large proportion of people who stay on the drug long-term.
The combination of weight gain, elevated blood sugar, and changes in cholesterol and triglycerides creates a cluster of cardiovascular risk factors that accumulates year after year. For a population already facing a life expectancy gap of 15 to 20 years compared to the general population, these metabolic effects are a significant contributor to early death from heart disease and stroke.
Why It’s Still Prescribed
Given all of this, it seems reasonable to ask why anyone would take clozapine at all. The answer is that for people with treatment-resistant schizophrenia, roughly one-third of everyone diagnosed with the condition, clozapine is the only medication with strong evidence of working. About 40% to 54% of treatment-resistant patients respond to clozapine after failing at least two other antipsychotics. No other drug comes close to that number for this population.
Clozapine also has a unique benefit no other antipsychotic shares: it is the only one with regulatory approval for reducing the risk of suicide in schizophrenia. A large population-based study following over 2,300 people with treatment-resistant schizophrenia found that those not taking clozapine had nearly twice the rate of death from any cause compared to those on it. Self-harm rates were also significantly higher on other antipsychotics. Perhaps most striking, the year after someone stopped clozapine, their mortality risk jumped by 2.65 times compared to when they were taking it.
This is the core paradox of clozapine. It is genuinely dangerous, requiring more monitoring and carrying more acute physical risks than any other psychiatric medication. But for the people who need it, not taking it is statistically more dangerous still. The risks are real, managed through constant vigilance, blood draws, and close clinical follow-up. The benefit is staying alive and functioning in a way that no alternative medication can reliably provide.